“Anyway, back to the MND trial, if it goes well (and certainly looks that way so far) I believe this will be the inflection point for the company and its sp.”
The question is Lastly, would we have been better off sticking to a Phase 1 MND Toxicology trial only? If we didn’t allow the interim analysis, we could have commenced the Phase 2 trial in Cancer, COVID19, and MND, ant the same time, after the Optimal Dose and toxicity was determined.
How do you think this will unfold now with successful results in MND interim analysis?
Regards,
Havelots
Ann: Epichem enters voluntary liquidation, page-128
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.015(6.25%) |
Mkt cap ! $109.4M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 22.5¢ | $133.9K | 573.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 303213 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 57592 | 2 |
View Market Depth
| Last trade - 15.46pm 18/10/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |